Skip to main content

Table 4 Organ in BF group

From: Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

BF group

Prostate (n = 80, %)

Cervix uteri (n = 54, %)

Breast (n = 29, %)

Uterus (n = 14, %)

Others (n = 68, %)

p value

Prim. Completion attribute

      

 Actual

30 (37.5 %)

18 (33.3 %)

13 (44.8 %)

3 (21.4 %)

18 (26.5 %)

0.283a

 Anticipated

43 (53.8 %)

29 (53.7 %)

15 (51.7 %)

9 (64.3 %)

36 (52.9 %

 None

7 (8.8 %)

7 (13.0 %)

1 (3.4 %)

2 (14.3 %)

14 (20.6 %)

Completion date attribute

      

 Actual

26 (32.5 %)

12 (22.2 %)

8 (27.6 %)

3 (21.4 %)

20 (29.4 %)

0.112a

 Anticipated

39 (48.8 %)

19 (35.2 %)

15 (51.7 %)

5 (35.7 %)

24 (35.3 %)

 None

15 (18.8 %)

23 (42.6 %)

6 (20.7 %)

6 (42.9 %)

24 (35.3 %)

First received

      

 1999–2004

12 (15.0 %)

11 (20.4 %)

1 (3.4 %)

1 (7.1 %)

19 (27.9 %)

<0.001a

 2005–2009

29 (36.2 %)

19 (35.2 %)

19 (65.5 %)

10 (71.4 %)

20 (29.4 %)

 2010–2015

39 (48.8 %)

24 (44.4 %)

9 (31.0 %)

3 (21.4 %)

29 (42.6 %)

Last changed

      

 2005–2009

4 (5.0 %)

4 (7.4 %)

2 (6.9 %)

0

12 (17.6 %)

0.202a

 2010–2015

76 (95.0 %)

50 (92.6 %)

27 (93.1 %)

14 (100 %)

56 (82.4 %)

Primary completion

      

 2000–2004

4 (5.5 %)

0

1 (3.6 %)

0

7 (13.0 %)

0.104a

 2005–2009

10 (13.7 %)

10 (21.3 %)

6 (21.4 %)

0

6 (11.1 %)

 2010–2015

36 (49.3 %)

27 (57.4 %)

17 (60.7 %)

8 (66.7 %)

28 (51.9 %)

 2016+

23 (31.5 %)

10 (21.3 %)

4 (14.3 %)

4 (33.3 %)

13 (24.1 %)

Completion year

      

 2000–2004

2 (3.0 %)

0

0

0

6 (13.0 %)

0.027a

 2005–2009

9 (13.6 %)

9 (27.3 %)

2 (8.3 %)

1 (12.5 %)

9 (19.6 %)

 2010–2015

31 (47.0 %)

16 (48.5 %)

11 (45.8 %)

5 (62.5 %)

17 (37.0 %)

 2016+

24 (36.4 %)

8 (24.2 %)

11 (45.8 %)

2 (25.0 %)

14 (30.4 %)

  1. aChi square test